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ABSTRACT 
 
Chronic infection with the hepatitis B virus (HBV) is endemic to sub-Saharan Africa 
and south-east Asia where it is a major risk factor for the development of cirrhosis and 
hepatocellular carcinoma (HCC). Currently available therapy is only effective in a small 
subset of chronic carriers. The development of novel treatment modalities for the management 
of HBV therefore remains an important global medical objective. Sequence plasticity of the 
HBV genome is limited by its small size and the overlapping nature of its open reading frames 
(ORFs). These features make HBV an ideal target for therapy based on nucleic acid 
hybridization. The use of ribozymes (RNA enzymes) and antisense molecules to inhibit gene 
expression is well documented. The recent discovery of RNA interference (RNAi) has added 
to the arsenal of therapy based on nucleic acid hybridization. RNAi is the process whereby 
short RNA duplexes (called short interfering RNA or siRNA) mediate the sequence-specific 
post-transcriptional silencing of genes homologous in sequence to the siRNA. siRNA function 
by guiding a protein complex (RNA Induced Silencing Complex or RISC) to target mRNA for 
degradation or translational repression. The protein X ORF (HBx ORF) is a conserved region 
of the HBV genome and is common to all viral transcripts. HBx is required for infection by 
the virus and plays an important role in the establishment of chronic infections in vivo as well 
as in the development of HCC. RNAi targeted against the HBx ORF may therefore prove 
useful as treatment of chronic HBV infection. 
 
Abstract   - vii - 
Plasmid based expression cassettes capable of endogenously generating short hairpin 
RNA (shRNA) targeted to the HBx ORF were constructed. The shRNA function as substrates 
for the RNAi machinery and are processed into siRNA. The ability of the expression cassettes 
to knockdown markers of HBV gene expression was tested in a human hepatoma cell line. A 
panel of 10 U6 promoter-driven shRNA expression vectors was generated. The U6 promoter 
(an RNA polymerase III promoter) is normally involved in the transcription of small nuclear 
RNA and as such is ideal for the generation of shRNA of precisely defined length. Three 
cytomegalovirus (CMV) promoter-driven shRNA expression cassettes incorporating 
ribozymes that produce defined hairpin sequences were also generated. The CMV promoter 
(an RNA polymerase II) promoter is involved in the transcription of large messenger RNA. 
Two hammerhead ribozymes lying 5’ and 3’ of the shRNA encoding sequence were 
incorporated into the cassette. Cis-cleavage by the ribozymes releases a shRNA of defined 
length thereby overcoming the limitations imposed by extraneous sequences from CMV 
promoter-driven transcription. U6 promoter-driven shRNA expression vectors efficiently 
knocked down markers of HBV replication in liver cells. The CMV promoter-driven 
expression vectors were incapable of inhibiting HBV gene expression; however shRNA 
generated in vitro from these vectors mediated efficient knockdown of HBV replication. 
shRNA-mediated inhibition of gene expression therefore holds promise as a novel treatment 
strategy for the management of HBV and other mobile genetic elements. 
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CHAPTER 1 
1 INTRODUCTION 
1.1 The Hepatitis B Virus 
 
 
1.1.1 Hepatitis B virus biology 
 
 
The hepatitis B virus (HBV) causes both chronic and acute infections of the liver. 
Chronic infection with HBV is a global medical problem as it is estimated that 350 million 
people worldwide are chronically infected with HBV (1). Chronic infection with HBV is a 
major risk factor for the development of cirrhosis and hepatocellular carcinoma (HCC). HCC 
is the fifth most important cancer worldwide in terms of sheer numbers (5.4% or 437,000 of 
new cancer cases) and fourth in mortality rates (8.2% or 427, 000 of total cancer-related 
deaths) (2). HBV and hepatitis C virus, are estimated to be the cause of 75% of HCC cases in 
developed countries and 85% of HCC cases in developing countries (2). An effective vaccine 
has been available for 20 years and in areas where HBV immunization has been introduced the 
incidence of chronic HBV infections and HCC has decreased (2). Vaccination however does 
not treat established infections. Currently, interferon-α (an immunomodulator) and the two 
nucleoside analogues, lamivudine and adefovir dipivoxil, are the only antiviral strategies 
licensed for the treatment of chronic HBV infection (3). The use of interferon-α and 
nucleoside analogues is only effective in a subset of chronic HBV carriers (i.e. HBV e antigen 
(HBeAg)-positive carriers). In addition, the use of nucleoside analogues leads to the 
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development of resistant strains of HBV (4). This highlights the need for the development of 
novel treatment strategies for the management of chronic HBV infection. The use of RNA 
interference (RNAi) to knockdown gene expression holds promise as a novel anti-HBV 
treatment strategy. The current investigation is aimed at developing treatment strategies 
capable of exploiting the RNAi pathway to inhibit HBV gene expression.  
 
1.1.2 HBV life cycle 
 
 
HBV belongs to the Hepadnaviridae family of viruses (1), and as the name suggests 
these viruses have DNA genomes and exhibit hepatotropism. HBV is an enveloped virus that 
has its partially double-stranded DNA genome encapsidated in a nucleocapsid together with 
the viral polymerase. Early events in the life cycle of HBV, including entry, uncoating and 
translocation of the viral genome to the nucleus (Figure 1.1) are poorly understood due to the 
lack of cell lines susceptible to HBV infection. HBV is thought to interact with an as yet 
unidentified receptor and enter its host cell by receptor-mediated endocytosis. Once the virus 
has entered the cell it is uncoated and translocated to the nucleus, where the partially double-
stranded DNA genome undergoes DNA repair to form covalently closed circular DNA 
(cccDNA) (5).  The cccDNA then serves as a template for the transcription of viral RNA by 
host RNA polymerase II. Transcription under the control of four internal promoters and the 
two viral enhancer elements, En1 and En2, produces pregenomic RNA as well as three classes 
of subgenomic mRNA from the cccDNA template (1). The subgenomic mRNA codes for the
Chapter 1   - 3 - 
 
 
Figure 1.1: Hepatitis B Virus life cycle. Upon entry into the host cell the partially double-stranded DNA 
genome is converted to cccDNA. cccDNA functions as template for the transcription of viral RNA. Pregenomic 
RNA is translated into polymerase, which first reverse transcribes the pregenome to generate the minus strand of 
the genome followed by plus strand synthesis. The DNA genome can re-enter the nucleus to form more cccDNA 
or be enveloped for secretion by Golgi apparatus. (Adapted from Seeger and Mason (1)). 
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three surface antigens and the X protein (HBx). Pregenomic RNA is a greater than genome 
length RNA with terminal sequence duplication, and codes for the viral polymerase and 
precore proteins (6). The pregenomic RNA also functions as a replication intermediate for the 
reverse transcription of the HBV genome. Pregenomic RNA is encapsidated into immature 
nucleocapsids together with the viral polymerase. Within these nucleocapsids the pregenome 
is reverse transcribed to generate the partially double-stranded DNA genome. Once reverse 
transcription is complete the nucleocapsids undergo maturation when an outer envelope is 
acquired and the mature virion is released from the cell. Alternatively, the nucleocapsids may 
be redirected to the nucleus for the formation of cccDNA.  
 
1.1.3 HBV genome structure and viral proteins 
 
HBV contains an approximately 3.2 kilobase (kb) partially double-stranded DNA 
genome (Figure 1.2). Viral particles mainly contain a complete minus strand with the viral 
polymerase covalently attached to its 5’ end. The circular structure of the HBV genome is 
maintained by the incomplete plus strand, which sits astride the 5’ and 3’ ends of the minus 
strand. The genome of HBV is organized into four open reading frames (ORFs) encoding the 
precore/core proteins, viral polymerase, HBx and the three HBV surface antigens (HBsAg), 
PreS1, PreS2 and S. Transcription from the four ORFs give rise to the pregenomic RNA and 
the three subgenomic mRNAs. A single polyadenylation signal results in all viral transcripts 
having identical 3’ ends. The 3.5 kb pregenomic RNA contains the ORFs for the translation of 
viral polymerase and the precore/core proteins. Translation of the precore/core ORF is 
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initiated at two different initiation sites. Precore protein is processed via the Golgi apparatus 
and secreted as HBeAg. Translation from the second initiation codon of the precore/core
 
 
Figure 1.2: Hepatitis B Virus genome organization.  Co-ordinates are shown relative to the single EcoRI 
restriction site. The partially double-stranded DNA genome is shown with the viral polymerase covalently 
attached. Different transcription initiation sites are represented on the HBV genome by circular and rectangular 
objects. Arrows immediately surrounding the HBV genome indicate the four open reading frames. The four outer 
arrows represent viral transcripts. Adapted from Passman, Weinberg, Kew and Arbuthnot (7). 
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ORF generates core proteins (HBcAg), which forms the nucleocapsid. The 2.4 kb RNA 
transcript encodes the PreS1 antigen whereas the 2.1 kb encodes the PreS2 and S antigens. 
The 0.9 kb RNA transcript codes for HBx. 
 
1.2 HBV Management 
 
An effective vaccine is at present available (1), vaccination however does not treat 
established infections. The immunomodulator, interferon-α, and the nucleoside analogues 
lamivudine and adefovir are currently the only licensed treatment strategies for the 
management of chronic HBV infection (4).  Patients chronically infected with HBV have 
attenuated T cell responses, whereas the rapid clearance of HBV during an acute infection is 
attributed to a robust T cell response (3). Therefore, the immunomodulator, interferon-α is 
used to boost the T cell response against HBV and in so doing aid in clearance of the virus (3). 
Interferon-α, however is only effective in chronic carriers with a high replicative state (i.e. in 
HBeAg positive carriers). The use of interferon-α is also associated with a number of adverse 
side effects, of which leucopoenia, fatigue and depression are the most common. Nucleoside 
analogues are chemically synthesized molecules that are structurally similar to naturally 
occurring nucleosides. The structural similarity of nucleoside analogues to nucleosides allow 
these molecules to be incorporated into HBV DNA during DNA polymerization (3). 
Incorporation of nucleoside analogues into the nascent DNA chain terminates polymerization, 
thereby inhibiting viral replication. Lamivudine has been shown to be equally effective in 
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HBeAg-negative carriers as in HBeAg-positive carriers.  The emergence of drug-resistant 
strains of HBV following treatment with lamivudine represents a major drawback to the use of 
nucleoside analogues. HBV polymerase like other RNA-dependant DNA polymerases 
contains the YMDD (tyrosine-methionine-aspartate-aspartate) motif in its catalytic site. 
Mutations within this motif (methionine to lysine (YVDD) and methionine to isoleucine 
(YIDD)) are known to confer resistance to lamivudine (3). 
 
 The development of novel treatment strategies for the management of chronic HBV 
therefore remains an important medical objective. One such approach is the use of ribozymes 
or RNA enzymes. Ribozymes are naturally occurring RNA molecules capable of sequence-
specific cleavage and splicing (8). Target site recognition is dictated by the ribozyme 
sequence, which is designed to be complementary to that of the target RNA. The anti-HBV 
activity of ribozymes have been demonstrated (7, 9). In recent years the use of RNA 
interference (RNAi) as a novel antiviral treatment modality (10-15) has become quite popular. 
RNAi is based on nucleic acid hybridization, where a ‘guide’ RNA binds to a complementary 
region in the ‘target’ RNA thereby mediating inhibition of the target RNA. HBV has a very 
compact genome consisting of overlapping ORFs with many of the viral transcripts coding for 
more than one protein. These characteristics severely limit the sequence plasticity of the HBV 
genome making it an ideal target for therapy based on nucleic acid hybridization. RNAi 
therefore represents a potentially effective treatment strategy for the management chronic 
HBV infections. 
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1.3 RNA Interference 
 
The term RNA interference or RNAi was first coined in 1998 when Andrew Fire and 
colleagues demonstrated that injection of double-stranded RNA (dsRNA) into the nematode 
worm Caenorhabditis elegans leads to the potent and specific silencing of genes homologous 
in sequence to the injected dsRNA (16). Not only was gene silencing effected throughout the 
body of the worm but RNAi was also observed in the first generation offspring. The effects of 
injecting dsRNA into the worms were reversible and therefore did not reflect a stable genetic 
change. Later the same year it was demonstrated that the dsRNA effectors of RNAi could also 
be delivered by feeding nematode worms with bacteria expressing dsRNA from recombinant 
plasmids (17). With the discovery that dsRNA was the effector molecule of RNAi two 
previously unexplained gene silencing phenomenon termed co-suppression in plants and 
quelling in fungi were linked to RNAi (18, 19).  
 
1.3.1 The mechanism of RNAi 
 
The development of a cell-free system capable of recapitulating RNAi in vitro 
provided a biochemical framework for experimental investigation of the mechanism of RNAi 
(20). RNAi is initiated by the introduction of dsRNA into cells (Figure 1.3). The dsRNA is 
processed into short RNA fragments (called short interfering RNA or siRNA) that are 21 to 22 
nucleotides (nt) in length with 2 nt 3’ overhangs (21). siRNA are processed from larger 
dsRNA by the ribonuclease (RNase) III, Dicer (22) and incorporated into a protein complex 
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called the RNA Induced Silencing Complex (RISC). The sense strand of the siRNA is 
removed in an ATP-dependent manner and the antisense strand (i.e. the strand complementary 
to the target mRNA) is retained (23, 24). The antisense strand of the siRNA functions by 
guiding RISC to mRNA with complementary sequence, where RISC mediates endonucleolytic 
cleavage and subsequent degradation of the target RNA. That siRNA mediate RNAi proved to 
be significant in the context of mammalian RNAi as dsRNA greater than 30 base pairs (bp) in 
size causes sequence non-specific knockdown of gene expression through the induction of the 
interferon response (25, 26). The discovery that 21 nt synthetically produced siRNA, which 
are small enough to avoid the interferon response, are able to induce RNAi in mammalian 
cells (27, 28) paved the way for mammalian RNAi studies. 
 
1.3.1.1 The random degradative PCR pathway 
 
In the nematode worm, C. elegans, induction of RNAi leads to the potent silencing of 
the targeted gene throughout the entire body of the worm. The RNAi effect may also be 
transferred to the first generation offspring.  An additional step during which amplification of 
siRNA occurs has been proposed to explain the spreading effect seen in C. elegans (29, 30).  
The antisense strand of a siRNA is proposed to act as a primer for an RNA-directed RNA 
polymerase (RdRP). Hybridization of the antisense strand of a siRNA to the target mRNA 
initiates RNA polymerization to generate a dsRNA, which is processed by Dicer to form 
secondary siRNA. The secondary siRNA may in be incorporated into RISC to function as 
guides or re-enter the random degradative PCR pathway. If random degradative PCR does
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Figure 1.3:  The RNA interference pathway. Long dsRNA is cleaved by Dicer into siRNA. The siRNA are incorporated into RISC and guide the 
protein complex to target mRNA for endonucleolytic cleavage. In plants and nematodes the siRNA may also function as primers for the RNA-
dependant RNA polymerization of target mRNA to generate dsRNA, which in turn is processed by Dicer to produce secondary siRNA. 
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hold true it may be predicted that the secondary siRNA would target a region of the mRNA 
that lies upstream of the primary siRNA target site (i.e. by transitive RNAi). Indeed, this 
proves to be the case (29, 30). When the gene for green fluorescent protein (gfp) is cloned 5’ 
of the gene for β-galactosidase (lacZ), siRNA targeted against lacZ leads to gfp silencing. On 
the contrary, when gfp is cloned 3’ of the lacZ gene, siRNA targeted against lacZ leads to the 
silencing of lacZ only. These results indicated that transitive RNA does occur, at least in the 
nematode worm, and leads to an amplification of the siRNA. The same cannot be said of 
RNAi in the fruitfly, Drosophila melanogaster or in mammals where siRNA have been shown 
to function as guides only and not as primers (31).  
 
1.3.1.2  MicroRNA 
 
MicroRNA (miRNA) are a family of small, non-coding RNA encoded within the 
genome that regulate sequence-specific gene expression at the post-transcriptional level. The 
first microRNAs to be identified, lin-4 and let-7 were initially classified as small temporal 
RNA (stRNA) (32). lin-4 and let-7 function in embryogenesis by repressing expression of 
their target genes. Repression is achieved through inhibition of translation (33). Certain 
characteristics were shared between stRNA and siRNA; both siRNA and stRNA are 21 nt in 
length and are processed from larger dsRNA precursors. The similarities between these two 
species of non-coding RNA prompted the investigation into the link between RNAi and 
stRNA expression (34-36). It was discovered that genes involved in RNAi regulate the 
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expression of stRNA.  These observations were followed by the identification of a whole host 
of microRNA (37-39).  
 
With the identification of the miRNA sequences an elucidation of their biogenesis soon 
followed (Figure 1.4). The  primary precursors of miRNA (pri-miRNA) are transcribed in the 
nucleus (40) and are processed into precursor miRNA (pre-miRNA) by the RNase III, Drosha 
(41, 42).  Following processing by Drosha, the pre-miRNA is exported to the cytoplasm by the 
Ran-GTP dependent cargo transporter Exportin-5 (43). In the cytoplasm the pre-miRNA is 
processed into the mature miRNA, which is incorporated into a miRNA nucleoprotein 
(miRNP) (44). In much the same way that siRNA function the mature miRNA guides the 
miRNP to target mRNA for translational repression (40). The miRNP was later shown to be 
the same protein complex involved in RNAi, i.e. RISC (45). This begs the question as to why 
do siRNA function by degrading mRNA when miRNA repress translation. It was later 
demonstrated that the different mechanism of action can be attributed to the degree of 
complementarity between the siRNA or miRNA and the target mRNA (46-48). If the siRNA 
or miRNA is completely complementary to the target mRNA inhibition will be by mRNA 
degradation. On the other hand if incomplete complementarity exists between the siRNA or 
miRNA and the target RNA silencing will occur by translational repression.  
 
Although most miRNA do not have an ascribed function they appear to play important 
roles in developmental regulation (49). The importance of miRNA for correct development 
has also been highlighted recently by the discovery of human cancers that can be attributed to
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Figure 1.4:  MicroRNA biogenesis. Polycistronic and monocistronic pri-miRNA are transcribed in the nucleus and processed in ~70 nt pre-miRNA. 
The pre-miRNA is exported to the cytoplasm by an exportin-5 mediated pathway, where it is processed by Dicer into mature miRNA. The mature 
miRNA associates with RISC and guides the complex to target mRNA for silencing by endonucleolytic cleavage or translational repression.  
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loss of miRNA function (50, 51) (for review see (52)). In addition to this, miRNA encoded by 
the Epstein-Barr virus have recently been identified, which are thought to function as viral 
regulators of host  and/or viral gene expression (53). 
 
1.3.2 Inducing RNAi 
 
In order to induce RNAi in mammalian cells the use of chemically synthesized siRNA 
is generally employed. Chemically synthesizing siRNA however is not always feasible due to 
the costs incurred. Therefore numerous methods of inducing RNAi have been developed. 
These can be broadly divided into in vitro generated siRNA and systems capable of expressing 
siRNA in mammalian cells.  
 
In vitro generation of siRNA. The first method employs run-off transcription of a short 
sequence of DNA encoding separate strands of the siRNA (54).  Double-stranded DNA 
sequences 38-39 nt in length are synthesized such that the first 18 nt encode the T7 RNA 
polymerase promoter followed by the sequence encoding either strand of the siRNA. Run-off 
transcription with the T7 RNA polymerase generates 20-21 nt fragments, which are annealed 
to form the siRNA. In vitro transcription from phage polymerases generates transcripts with a 
5’ nucleotide triphosphate. This characteristic is thought to be recognized by mammalian cells 
as foreign and has been demonstrated to lead to the induction of the interferon response (55). 
The second method uses the products of hydrolysis of recombinant Dicer or Escherichia coli 
RNase III to induce RNAi (56, 57). Large dsRNA homologous to the target gene is transcribed 
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in vitro and treated with recombinant human Dicer or E. coli RNase III to produce a pool of 
siRNA capable of mediating efficient RNAi. Using a pool of siRNA is not ideal as it increases 
the probability of one of the siRNA exhibiting off-target effects. The use of deoxyribozymes 
(catalytic DNA molecules) to digest in vitro transcribed RNA to produce siRNA has also been 
described (58). Since siRNA-mediated post-transcriptional gene silencing takes place in the 
cytoplasm the use of RNA has the advantage that only the plasma membrane needs to be 
crossed during delivery for the siRNA to be functional. The disadvantage in using chemically 
synthesized or in vitro transcribed siRNA lies in the instability of RNA and is therefore prone 
to degradation. The high turnover rate of RNA also means that the knockdown achieved will 
only be maintained for a limited time period. If RNAi is to be used for the management of 
chronic infections knockdown should ideally be maintained for longer periods of time than 
can be achieved when using siRNA. The use of siRNA expression systems would allow for 
knockdown to be maintained for longer periods of time since the siRNA could be expressed 
continuously.     
 
siRNA expression systems. Expression systems under the control of RNA polymerase 
II (59) and RNA polymerase III (60-65) promoters have been developed. These expression 
systems are capable of endogenously transcribing either individual strands of a siRNA (60) or 
short hairpin RNA (shRNA) precursors, which function as substrates for Dicer (59, 61-65). 
RNA polymerase III promoters (pol III promoters) are generally favoured as these are 
normally involved in the transcription of small RNA species and are therefore ideal for the 
production of siRNA or shRNA. Expression from pol III promoters however is ubiquitous (i.e. 
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expressed in all cell types) and therefore expression cannot be controlled in a tissue specific 
manner. Transcription from pol III promoters is also constitutive and as such dosage cannot be 
controlled. RNA polymerase II promoters (pol II promoters) on the other hand exhibit tissue-
specific expression and may be employed to express shRNA in specific tissues. Pol II 
promoters are normally involved in the transcription of large messenger RNA. Generation of 
shRNA under the transcriptional control of a pol II promoter therefore yields RNA transcripts 
containing unwanted sequences, which may interfere with the processing of the shRNA. 
Expression systems generating shRNA that mimic the structure miRNA precursors have also 
been described (66, 67). These systems also employ the pol II promoter and require processing 
by Drosha to release the shRNA from the larger RNA transcript.  An additional disadvantage 
in using DNA expression systems to effect knockdown of a gene of interest is that the DNA 
needs to be delivered to the nucleus. The DNA encoding the siRNA or shRNA expression 
systems therefore has to cross the plasma membrane as well as the nuclear membrane before 
transcription can occur.  
 
1.4 RNAi-mediated inhibition of HBV 
 
Several sites of the HBV genome have been targeted in studies to assess efficiency of 
using RNAi against HBV (10, 12, 14). To date, siRNA sequences have been evaluated in vitro 
and in vivo in a murine model of HBV replication. McCaffrey and colleagues (14) assessed the 
anti-HBV efficacy of a panel of six U6 promoter cassettes that encoded hairpin RNA 
sequences. The data demonstrated inhibition of markers of HBV gene expression with some 
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variation in the efficiency of the hairpin-encoding cassettes. Giladi and colleagues (10) 
assessed the efficacy of five synthetic siRNA duplexes that targeted different sites within the 
surface ORF of HBV. The siRNA sequences diminished HBsAg production from a 
polymerase deficient HBV plasmid. This is an important property that is distinct from anti-
HBV nucleoside analogues, which have inhibitory effects on viral DNA synthesis and require 
viral replication to be effective. In another study (12), inhibition of HBsAg and HBeAg 
secretion was observed in mice treated with synthetic RNA duplexes, which targeted the core 
and surface genes of HBV. HBV antigen secretion and also the production of HBV RNA (as 
measured by RT-PCR) were diminished by both siRNA duplexes, and the siRNA that targeted 
the surface region was a more effective inhibitor of antigen secretion. Comparison of anti-
HBV activity of synthetic and pol III-derived small hairpin RNA shows that, although both 
types of sequence effectively inhibit HBV gene expression, synthetic siRNA duplexes may 
have a more rapid effect (10). However, small hairpin constructs generated endogenously from 
pol III promoters may have more sustained effects. Complete characterization of the 
differences between these two classes of interfering RNA is yet incomplete. 
 
This project entailed the construction and evaluation of two shRNA expression cassettes. 
The first expression cassette employs the U6 promoter to drive expression of shRNA with a 
precisely defined size. The shRNA function as substrates for processing by Dicer into siRNA, 
which are targeted against the HBx ORF. A PCR-based technique for the rapid generation of 
U6 promoter driven shRNA expression cassettes (65), was initially employed to identify 
sequences capable of effectively inhibit markers of HBV replication. The second cassette 
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employs an RNA polymerase II promoter (the cytomegalovirus (CMV) promoter) to drive the 
production of RNA transcripts containing ribozymes lying on either side of a shRNA 
sequence. Cis-cleavage by the ribozymes releases the shRNA, which in turn enters the RNAi 
pathway to mediate knockdown of HBV gene expression.  
 
The ribozyme–shRNA (Rz-shRNA) expression cassette incorporates the most 
favourable features of the use of RNA or the use of DNA into its design. The fact that it is a 
plasmid-based expression cassette allows for the continuous expression of shRNA thereby 
prolonging knockdown of the targeted gene. Use of a pol II promoter allows for tissue-specific 
expression of shRNA. The problem of unwanted sequences generated under pol II promoter-
driven transcription is overcome by the incorporation of ribozymes in the design of the 
expression cassette to allow for the production of shRNA of defined length. Alternatively the 
expression cassette could be used for the exogenous production of shRNA. The shRNA 
generated from cis-cleavage by the ribozymes do not contain 5’ triphosphates and would 
therefore not induce the interferon response.  
 
The expression cassettes were designed to endogenously (and exogenously in the case of 
the Rz-shRNA cassette) generate shRNA targeted against the HBx ORF. Transcription from 
the HBV genome is under the control of four internal promoters but ends with a single 
termination signal. All viral transcripts therefore share a common 3’ end. Since the HBx ORF 
generates the smallest transcript it represents the sequence common to all viral transcripts. 
RNAi mediated against the HBx ORF would therefore target all viral transcripts. HBx plays a 
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vital role in the establishment of a successful viral infection in vivo. HBx has also been 
implicated in the development of HCC. These factors make HBx an ideal target for the 
development of antiviral therapy. 
 
A total of ten sites within the HBx ORF were chosen as target sites for RNAi-mediated 
inhibition of HBV. These sites represent the most conserved regions of the HBx ORF as 
determined by alignment of South African isolates of HBV. To establish whether the shRNA 
targeted to these sites might inadvertently target unrelated genes within the human genome a 
BLAST search was performed. HBx coordinates 1168-1192 received 98 hits. The single hit 
showing significant homology (91%) with a human cDNA had 2 nt mismatches occurring 
towards the center of the sequence and is therefore unlikely to be silenced. Similar search 
results were obtained for most of the target sites. The exception (HBx1678-1702) received 98 hits 
with one showing a 95% sequence homology and a single nucleotide mismatch occurring 
towards the 3’ end of the sequence. The shRNA targeted against HBx1678-1702 may therefore 
cross react with a human cDNA clone. 
 
1.5 Aims 
 
The aim of this project was the construction and evaluation of two expression cassettes 
capable of generating shRNA sequences targeted to the HBx ORF. The first expression 
cassette employs the U6 promoter to drive expression of shRNA of defined sequence and size. 
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shRNA are processed by Dicer into siRNA, which enter the RNAi pathway to mediate 
knockdown of HBV gene expression. The second expression cassette is a self-cleaving 
construct under the control of the cytomegalovirus (CMV) promoter, an RNA polymerase III 
promoter. Transcription from the CMV promoter produces a transcript containing self-
cleaving ribozymes lying on either side of a shRNA sequence. Cis-cleavage by the ribozymes 
releases the shRNA sequence, which in turn enters the RNAi pathway. The ability of these 
expression cassettes to mediate inhibition of HBV replication was assessed in the human 
hepatoma cell line, Huh7. 
 
 
Chapter 2  - 21 - 
CHAPTER 2 
2 MATERIALS AND METHODS 
2.1 Target and Reporter Plasmids 
 
 
2.1.1 The target plasmid 
 
 
The construction of the target plasmid pCH-9/3091 has been previously described by 
Nassal and colleagues (68). Briefly, pCH-9/3091 contains wild-type HBV genome with 
terminal repeats under the control of the CMV immediate early promoter-enhancer. The 
terminal repeats functionally mimic the circular nature of the HBV genome. As would occur 
normally during HBV replication, transcription from pCH-9/3091 generates a greater than 
genome length pregenomic RNA. cccDNA may then be reverse transcribed from the 
pregenomic RNA template. Transcription from pCH-9/3091 therefore simulates HBV 
replication. 
 
2.1.2 The reporter plasmid 
 
Construction of the reporter plasmid expressing enhanced green fluorescent protein 
(EGFP) as a marker of HBV replication has been previously described by Passman and 
colleagues (7). The reporter plasmid, pCH-EGFP, was generated by replacing the preS2/S 
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ORF of pCH-9/3091 with a sequence encoding EGFP. To generate pCH-EGFP, the DNA 
sequence coding for EGFP was amplified by PCR from the plasmid vector pBI-EGFP 
(Clontech, Palo Alto, USA). The amplicon was digested with XhoI and XbaI and cloned into 
the equivalent sites of the mammalian expression vector, pCI-neo (Promega, WI, USA) to 
generate pCI-EGFP. The DNA sequence encoding EGFP was then digested out of pCI-EGFP 
with XhoI and XbaI and cloned into the XhoI and SpeI sites of pCH-9/3091 to generate pCH-
EGFP. 
 
2.2 U6 shRNA Expression Vectors 
 
2.2.1 Design of shRNA sequences targeted against the HBx ORF 
 
Full genome sequences of South African HBV isolates were aligned with the 
Bioinformatics programme GeneDoc (69) and the most conserved regions of the HBx ORF 
were chosen as target sites. A panel of 10 shRNA targeted against the most conserved regions 
of the HBx ORF were designed. The shRNA were designed with 25 nt stems and the loop 
sequence of miR-23. Hairpins with stems greater than 21 nt exhibit improved processing by 
Dicer and miRNA loop sequences improve translocation of the hairpin to the cytoplasm (64). 
To aid in cloning, GU or CA mismatches were incorporated into the sequence of the stem 
structures. The mismatches were introduced into the sequence encoding the sense strand in 
order to maintain complete complementarity between the antisense (guide) strand and its
Chapter 2  - 23 - 
target site within the HBx ORF.  
 
2.2.2 Construction of U6 shRNA expression vectors targeted against the 
HBx ORF 
 
Expression cassettes capable of endogenously generating shRNA targeted against the 
HBx ORF were constructed in accordance with the PCR-based technique developed by 
Castanotto, Li and Rossi (65) with some modifications. The expression cassettes were 
incorporated into the pGEM®-T Easy PCR Cloning vector (Promega, WI, USA). 
Oligonucleotides encoding shRNA sequences were synthesized by phosphoramidite chemistry 
(Inqaba Biotechnology, South Africa). Each shRNA was encoded for by two staggered 
oligonucleotides (refer to Table 2.1). A universal primer complementary to the 5’ end of the 
U6 promoter was also synthesized (5’-CTA ACT AGT GGC GCG CCA AGG TCG GGC 
AGG AAG AGG G-3’).  
 
The human U6 promoter was amplified by PCR (PCR Master Mix; Promega, WI, 
USA) using the universal U6 primer and the primer encoding the first half of the shRNA (U6 
shRNAx.1) in the first step of the two-step PCR (Figure 2.1). PCR products from the first step 
were then amplified by PCR using the universal U6 primer and the primer encoding the 
second half of the shRNA (U6 shRNAx.2) during the second step of the two-step PCR to 
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Table 2.1:  Oligonucleotide sequences used in the generation of shRNA expression constructs.  
HBx1168-1192
 
U6 shRNA2.1 
 
U6 shRNA2.2 
 
 
 
5’-TGACGTGACAGGAAGCGTTAGCAGACACTTGGCATAGGCCCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAAGGTCTGTGCCAAGTGTTTGCTGACGTGACAGGAAGCGTTA-3’ 
HBx1432-1456
 
U6 shRNA6.1 
 
U6 shRNA6.2 
 
 
 
5’-GGACGTGACAGGAAGCGTTCGTGGGATTCAGCGTCGATGGCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAACCGTCGGCGCTGAATCCCGCGGACGTGACAGGAAGCGTTC-3’ 
HBx1514-1538
 
U6 shRNA7.1 
 
U6 shRNA7.2 
 
 
 
5’-CTTTATGACAGGAAGCAAAGAGAGATGCGCCCCATGGCCGCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAACGACCACGGGGCGCACCTCTCTTTATGACAGGAAGTAAAG-3’ 
 
HBx1518-1542
 
U6 shRNA8.1 
 
U6 shRNA8.2 
 
 
 
5’-ACGCGTGACAGGAAGCGTGTGAAGAGAGGTGTGCCCTGTGCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAACACGGGGCGCACCTCTCTTTACGCGTGACAGGAAGCGTGT-3’ 
 
HBx1575-1599
 
U6 shRNA10.1 
 
U6 shRNA10.2 
 
 
 
5’-CTCTGTGACAGGAAGCAGAGGCGAAGCAAAGCGCACACGACGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAACCGTGTGCACTTCGCTTCACCTCTGTGACAGGAAGCAGAG-3’ 
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HBx1580-1604
 
U6 shRNA11.1 
 
U6 shRNA11.2 
 
 
 
5’-CACGTTGACAGGAAGATGTGTAGAGGTGAAGCGAGGTGTACGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAATGCACTTCGCTTCACCTCTGCACGTTGACAGGAAGATGTG-3’ 
 
HBx1640-1664
 
U6 shRNA12.1 
 
U6 shRNA12.2 
 
 
 
5’-GGACTTGACAGGAAGAGTTCTTTTATGTAGGACTTTGGGCCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAAGCCCAAGGTCTTACATAAGAGGACTTGACAGGAAGAGTTC-3’ 
 
HBx1678-1702
 
U6 shRNA14.1 
 
U6 shRNA14.2 
 
 
 
5’-GAGGCTGACAGGAAGGCTTCAAGGTTGGTTGTTGACGTTGCGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAACAATGTCAACGACCGACCTTGAGGCTGACAGGAAGGCTTC-3’ 
 
HBx1774-1798
 
U6 shRNA17.1 
 
U6 shRNA17.2 
 
 
 
5’-TTGGTTGACAGGAAGACTAATTTGTGCCTACAGCTTCTTACGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAATAGGAGGCTGTAGGCATAAATTGGTTGACAGGAAGACTAA-3’ 
 
HBx1863-1887
 
U6 shRNA20.1 
 
U6 shRNA20.2 
 
 
 
5’-CTTGGTGACAGGAAGCCAAAGCACAACTCGGAGGCTCGAACGGTGTTTCGTCCTTTCCACA-3’ 
 
5’-CCCAGATCTACGCGTAAAAAATTCAAGCCTCCAAGCTGTGCCTTGGTGACAGGAAGCCAAG-3’ 
 
Complementary sequences are indicated in bold. 
The region complementary to the U6 promoter is italicized. 
HBx target sites are underlined. 
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generate a complete U6 shRNA expression cassette. The completed cassette consists of a U6 
promoter followed by the sequence encoding the shRNA and the terminator sequence 
(TTTTTT). For each PCR the reaction conditions were as follows: Initial denaturation at 95°C 
for 2 minutes; followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C 
for 30 seconds and extension at 72°C for 1 minute; a final extension step was carried out at 
72°C for 7 minutes. 
 
The amplicons were run on 0.8% agarose gels, excised and purified using the 
MinElute™ Gel Extraction Kit (Qiagen, CA, USA). The purified fragments were ligated into 
the pGEM®-T Easy Cloning vector according to the manufacturer’s instructions (Promega, 
WI, USA) (Figure 2.2). Purified U6 shRNA expression cassettes at a 20× molar excess to 
pGEM®-T Easy vector were incubated at 15°C overnight in a 10 µl reaction volume 
containing T4 DNA Ligase (Promega, WI, USA). Five microlitres of the ligation mix was 
used to transform 100 µl of chemically competent E. coli (DH5α, Invitrogen, CA, USA) (for 
preparing and transforming chemically competent E. coli see Appendix 6.1.1). The 
transformed E. coli were plated on Luria Bertani ampicillin positive, X-gal, IPTG positive 
agar plates (see Appendix 6.1.2) and incubated at 37°C overnight. Colonies containing an 
insert (white colonies) were selected and screened by restriction enzyme digestion with BglII 
and SpeI. Plasmids positive for the correct sized insert (pG-U6 shRNA) were sequenced 
(Inqaba Biotechnology, South Africa) to ensure that correct sequence fidelity was maintained. 
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Figure 2.1: Schematic representation of PCR-based technique for the generation of U6 shRNA expression cassette. Transcription from the expression 
cassette generates a shRNA sequence. 
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Figure 2.2: Schematic representation of cloning procedure for the generation of U6 shRNA expression plasmids. 
 
 
2.3 U6 shRNA-mediated Inhibition of HBV Gene Expression 
 
2.3.1 Plasmid preparation 
 
U6 shRNA as well as target and reporter plasmids were prepared with the EndoFree® 
Plasmid Maxi Kit (Qiagen, CA, USA) (refer to Appendix 6.1.3). 
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2.3.2 Transfection of cultured human hepatocytes with U6 shRNA 
expression cassettes 
 
The human hepatoma cell line, Huh7 was maintained in RPMI growth medium 
(Appendix 6.1.4) supplemented with 2.5% foetal calf serum (FCS), penicillin (100 000 U/ml) 
and streptomycin (100 µg/ml) (Gibco BRL, UK). One day before transfection, 2.0-2.5 × 105 
cells were seeded in 2 cm diameter dishes (Costar®, Corning Inc, NY, USA) in 2 ml RPMI 
growth medium. Five hours prior to transfection the RPMI growth medium was replaced with 
2 ml RPMI supplemented with 10% FCS but without any antibiotics. 
 
Each transfection sample was prepared as follows: 3 µg of pG-U6 shRNA and 6 µg 
pCH-9/3091 or pCH-EGFP were thoroughly mixed in 250 µl Opti-MEM I (Invitrogen, CA, 
USA). Three microlitres of Lipofectamine 2000 (Invitrogen, CA, USA) was diluted in 250 µl 
of Opti-MEM I and incubated at room temperature for 5 minutes. After the 5 minute 
incubation the diluted DNA was mixed with the diluted Lipofectamine 2000 and the mixture 
incubated for 20 minutes at room temperature to allow the DNA-Lipofectamine 2000 lipid 
complexes to form. Thereafter, 500 µl of transfection sample was added per well to the 6-well 
plate seeded with Huh7 cells. The cells were incubated for 24-48 hours at 37°C in a humidified 
incubator with 5% CO2.  
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2.3.3 Assay for markers of HBV expression 
2.3.3.1  EGFP expression 
 
Cells co-transfected with pCH-EGFP were replenished with RPMI growth medium 24-
hours post-transfection and incubated for an additional 24 hours at 37°C in a humidified 
incubator with 5% CO2.  Forty eight hours post-transfection cells were assayed for EGFP 
expression by Fluorescence Microscopy and Flow Cytometry.  
The cells were analysed by confocal microscopy (Axiovert 100M, Zeiss, Germany) 
under a FITC filter to identify green fluorescent cells. 
Growth medium was removed and cells washed with shaking in saline containing 
0.01% EDTA at 37°C for 10 minutes. The saline was removed, 100 µl of 0.5× trypsin added 
and the cells incubated for an additional 5 minutes at 37°C. After the 5 minute incubation, 900 
µl of saline containing 1% FCS was added and the cells aspirated to ensure complete 
dissociation from culture plate. Cells were transferred to flow cytometry tubes and green 
fluorescent cells analysed with a Beckman-Coulter EPICS XL Flow cytometer (Beckman, CA, 
USA). Cells were identified by forward scatter and side scatter with the mean channel number 
within the 60-80 range. EGFP fluorescence was detected at 450 nm.  
2.3.3.2 HBsAg secretion 
 
 
Twenty-four hours post-transfection the medium was collected from cells co-
transfected with pCH-9/3091 and HBsAg secretion measured (National Health Laboratory 
Services, South Africa). HBsAg secretion was measured by the electrochemiluminescence 
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immunoassay or ECLIA (Roche, Germany). Briefly, 50 µl of the growth medium is incubated 
with a biotinylated monoclonal HBsAg-specific antibody and a monoclonal HBsAg-specific 
monoclonal antibody labelled with ruthenium to form a sandwich complex with HBsAg. 
Streptavidin-coated microparticles are added to this mixture to bind the complex to the 
microparticles by the biotin-streptavidin interactions. The microparticles are magnetically 
captured on the electrode of the measuring cell. Chemiluminescence is induced by applying 
voltage to the electrode, the emission is measured and HBsAg quantified. 
 
2.4 CMV Ribozyme-shRNA Expression Vectors 
 
2.4.1 Designing Ribozyme-shRNA expression cassettes targeted against 
the HBx ORF 
 
A panel of three Ribozyme-shRNA (Rz-shRNA) expression cassettes targeting the 
same regions targeted by pG-U6 shRNA7, pG-U6 shRNA10 and pG-U6 shRNA20 were 
designed. The Rz-shRNA expression cassette consisted of a sequence of DNA encoding a 
shRNA flanked on its 5’ and 3’ ends by two hammerhead ribozymes (Figure 2.3). The 
hairpins were designed to mimic the structure of miR-30 (66, 67). The sequence of the basal 
stem and the loop of miR-30 were retained but the sequence of the internal stem was altered to 
target regions within the HBx ORF.  
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2.4.2 Construction of Rz-shRNA expression vectors targeted against the 
HBx ORF 
 
2.4.2.1 Generation of Ribozyme component of Rz-shRNA expression 
cassette 
 
 
A generic cloning cassette containing the 3’ and 5’ ribozymes separated by a spacer of 9 nt 
was generated in the mammalian expression vector pCI-neo (Figure 2.4). This was used for 
the subsequent insertion of shRNA-encoding sequences. Oligonucleotides coding for the 5’ 
and 3’ ribozymes of the Rz-shRNA cassette were synthesized by standard phosphoramidite 
chemistry (Inqaba Biotechnology, South Africa) (Table 2.2). Double-stranded DNA sequences 
encoding the 5’ ribozyme fragment (5’Rz*) was produced by amplifying the 5’Rz* forward 
and reverse primers by PCR (PCR Master Mix, Promega, WI, USA). Similarly, the 3’ 
ribozyme fragment (3’Rz*) was amplified as a double-stranded sequence by subjecting 3’Rz* 
forward and reverse primers to PCR. The PCR conditions were as follows: Initial denaturation 
at 95°C for 2 minutes; 30 cycles of denaturation at 95°C for 30 seconds, annealing at 48°C for 
30 seconds and extension at 72°C for 30 minutes; and a final extension step at 72°C for 2 
minutes. 
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Figure 2.3: Ribozyme shRNA expression cassette. Transcription generates a full length transcript which folds into its active conformation. Cis-
cleavage by the ribozymes releases the shRNA sequence. 
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Table 2.2: Oligonucleotide sequences for the generation of double-stranded 5’ and 3’ ribozyme fragments.  
 
 
5’Rz* F 
5’Rz* R 
 
5’-GATCCTCGAGTCTAGACGCCTGATGAGTCCGTGAGGACGAAACGAAT-3’ 
5’-GATCTTGGATCCTTGAATTCTGATCAGAATTCGTTTCGTCCTCACGG-3’ 
 
3’Rz* F 
3’Rz* R 
 
5’-GATCAAGGATCCAAGGGCCCCCGCGGGGGCCCCTGATGAGAGGAGT-3’ 
5’-GATCGTCGACACTAGTTGCTTTCGAGGCACTCCTCTCATCAGGGGC-3’ 
Complementary regions are indicated in bold. 
Ribozyme encoding sequences are underlined. 
 
  The 5’ and 3’ ribozyme fragments were subjected to agarose gel electrophoresis and 
eluted with Qiagen’s MinElute™ Gel Extraction Kit. The purified fragments were ligated into 
the pGEM®-T Easy PCR cloning vector at 20× molar excess overnight at 15°C in a 10 µl 
reaction volume.  Chemically competent E. coli (DH5α) were transformed with 5 µl of the 
ligation mix and plated on Luria Bertani ampicillin positive, X-gal, IPTG positive agar plates. 
The plates were incubated overnight at 37°C. Clones positive for the 5’Rz* insert (pG-5’Rz*) 
were screened for correct orientation by restriction with BamHI and SpeI. Clones positive for 
the 3’Rz* insert (pG-3’Rz*) were screened for correct orientation by restriction with BamHI 
and XbaI. Clones in the correct orientation were sequenced (Inqaba Biotechnology, South 
Africa).  
 
To combine the 5’ and 3’ ribozyme sequences into a single vector, pG-5’Rz* and pG-
3’Rz* were each digested with both ScaI and BamHI. The vector fragments containing the 
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ribozyme components were ligated together in a 20 µl reaction volume containing T4 DNA 
Ligase (New England Biolabs, MA, USA). The ligation reaction was incubated at 15°C 
overnight. Chemically competent DH5α E. coli were transformed with 10 µl of the ligation 
mix and plated on Luria Bertani ampicillin positive, X-gal, IPTG positive agar plates and 
incubated at 37°C overnight. Clones positive for both inserts (pG-Rz) were screened with 
EcoRI and sequenced to confirm that sequence fidelity was maintained.  
  
To incorporate the DNA sequence encoding the 5’ and 3’ ribozymes into a mammalian 
expression vector, pCI-neo was digested with XhoI and SalI. After a 2 hour incubation period, 
10 U of calf intestinal phosphatase (Roche, Germany) was added to the digestion reaction and 
incubated at 37°C for 30 minutes.  The pCI-neo backbone was resolved on a 0.8% agarose gel, 
excised and purified from the gel slice with Qiagen’s MinElute™ Gel Extraction Kit. The 
DNA sequence encoding the 5’ and 3’ ribozymes was digested out of pG-Rz with the 
restriction enzymes XhoI and SalI, subjected to agarose gel electrophoresis, excised and 
purified from the gel. A ligation reaction was set up with the 5’/3’ ribozyme fragment at a 50× 
molar excess to pCI-neo vector backbone in a 20 µl reaction volume containing T4 DNA 
Ligase (New England Biolabs, MA, USA). The ligation mixture was incubated at 15°C 
overnight. Chemically competent E. coli (DH5α) were transformed with 10 µl of the ligation 
mix, plated on ampicillin positive Luria Bertani agar plates and incubated at 37°C overnight. 
Clones positive for single unit inserts (pCI-Rz) were screened with HindIII. Single unit clones 
were screened for correct orientation with XhoI and SalI. 
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Figure 2.4: Diagrammatic illustration of cloning strategy for the generation of the ribozyme component of the 
Rz-shRNA expression cassette. 
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2.4.2.2  Generation of shRNA component of Rz-shRNA expression cassette 
 
 
DNA sequences encoding the three shRNA were initially cloned into the pGEM®-T 
Easy PCR cloning vector (Figure 2.5A). Oligonucleotides encoding the shRNA were 
synthesized by standard phosphoramidite chemistry (Inqaba Biotechnology, South Africa). 
The oligonucleotides encoding shRNA1, shRNA2 and shRNA3 (Table 2.3) were amplified by 
PCR (PCR Master Mix, Promega, WI, USA) to generate double-stranded sequences. The 
shRNA fragments (shRNA*) were run on a 0.8% agarose gel, excised and purified. A ligation 
of purified shRNA* at a 20× molar excess to pGEM®-T Easy cloning vector was set up in a 
10 µl reaction volume  and incubated overnight at 15°C. Five microlitres of the ligation mix 
was used to transform chemically competent E. coli (DH5α). Transformed E. coli were plated 
on Luria Bertani agar plates positive for ampicillin, X-gal and IPTG. Agar plates were 
incubated overnight at 37°C. Plasmids produced from individual bacterial colonies (clones) 
were screened with EcoRI to identify plasmids positive for hairpin encoding sequences. 
Positive clones were sequenced (Inqaba Biotechnology, South Africa). 
 
To clone the shRNA sequences into pCI-Rz the restriction endonuclease sites BclI and 
SacII were incorporated into the hairpin sequence by amplifying pG-shRNA1*, pG-shRNA2* 
and pG-shRNA3* with primers containing the sequence for these sites (BCL-Fwd 5’- GAT 
CTG ATC AGA TCG AAT TCG TC -3’ and SAC-Rev 5’- GAT CCC GCG GGA TCG GGC 
CCG AG -3’). The shRNA amplicons (shRNA**) were cloned into the pGEM®-T Easy 
cloning vector. Clones positive for an insert were sequenced (Inqaba Biotechnology, South
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Africa).  
Table 2.3: Oligonucleotides encoding shRNA sequences.  
 
HBx1514-1538
shRNA1* F 
shRNA1* R 
 
5’-GATCGAATTCGTCGCGCCCGCGGGGCGCACTTCTCTTCTGTGAAGCCACAGATGG-3’
5’-GATCGGGCCCGAGCAACCACGGGGCGCACCTCTCTTCCCATCTGTGGCTTCACAG-3’
HBx1575-1599
shRNA2* F 
shRNA2* R 
 
5’-GATCGAATTCGTCGCGACGTGTGTACTTCGCTTCGCCCTGTGAAGCCACAGATGG-3’ 
5’-GATCGGGCCCGAGCACCGTGTGCACTTCGCTTCACCCCCATCTGTGGCTTCACAG-3’
HBx1863-1887
shRNA3* F 
shRNA3* R 
 
5’-GATCGAATTCGTCGCGCTCAGGCCTCCAAGTTGTGCCCTGTGAAGCCACAGATGG-3’ 
5’-GATCGGGCCCGAGCATTCAAGCCTCCAAGCTGTGCCCCCATCTGTGGCTTCACAG-3’
Complementary regions are indicated in bold. 
HBx target sites are underlined. 
 
2.4.2.3 Generation of Rz-shRNA combination expression vector 
 
The complete Rz-shRNA combination cassette was generated in the mammalian 
expression vector pCI-neo (Figure 2.5B). pCI-Rz, pG-shRNA1**, pG-shRNA2** and pG-
shRNA3** were passaged through the dam negative, dcm negative strain of E. coli, GM161 
(for preparation and transformation of chemically competent E. coli refer to Appendix 6.1.1) . 
The shRNA sequences were digested out of pG-shRNA1**, pG-shRNA2** and pG-shRNA3** 
with the restriction enzymes BclI and SacII. Following digestion with BclI and SacII the 
shRNA sequences were cloned into the equivalent sites of pCI-Rz to generate pCI-Rz- 
shRNA1, pCI-Rz-shRNA2 and pCI-Rz-shRNA3. Sequence fidelity was checked by manual
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Figure 2.5: Schematic representation of cloning strategy for the generation shRNA component of the Rz-shRNA 
expression cassette (A) and subsequent insertion of shRNA sequences into pCI-Rz to generate the complete Rz-
shRNA expression cassette (B). 
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sequencing (Appendix 6.1.5). 
  
2.4.3 Testing Rz-shRNA Combination Cassette 
 
2.4.3.1  In vitro transcription assay and RNA purification 
 
The Rz-shRNA expression vectors were linearized with SalI to generate template for 
transcription from the T7 promoter and XhoI to generate template for transcription from the T3 
promoter. Radiolabelled RNA was transcribed from linearized template DNA using the 
Riboprobe® Combination System - T3/T7 RNA Polymerase (Promega, WI, USA) according 
to manufacturer’s instructions. Briefly, 2 μg of template DNA, 10× Transcription buffer 
(Promega, WI, USA), 20 U RNasin, 2.5 mM rATP, 2.5 mM rGTP, 2.5 mM rUTP, 100 μM 
rCTP and 20 μCi of α-32P rCTP (3000 Ci/mmol; Perkin Elmer, MA, USA) was incubated at 
37°C for 30 minutes with 20 U of T7 (SalI template) or T3 (XhoI template) RNA Polymerase 
in a 20 µl reaction volume. The reaction was stopped by addition of 10 µl of RNA loading 
buffer (Promega, WI, USA). Five microlitres of the transcription reaction was run on a 41 cm 
10% denaturing polyacrylamide gel until the xylene cyanol dye front had migrated 30 cm 
down the gel. Gels were subjected to autoradiography for 30 minutes at -70°C. 
 
The remaining T7 transcription reaction was run on a 20 cm 10% polyacrylamide gel 
until the xylene cyanol dye front had run approximately 15 cm. The gel was subjected to 
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autoradiography for 5-10 minutes and the autoradiograph used to locate full- and intermediate-
length transcripts. The RNA fragments were excised and recovered from the gel slice using 
the crush and soak method (see Appendix 6.1.6).  
 
2.4.3.2 Ribozyme cis-cleavage assays 
 
The purified RNA was resuspended in 62.5 mM Tris-HCl (pH 8.0). Twenty microlitres 
of resuspended RNA was heated at 95°C for 5 minutes and allowed to cool to room 
temperature. Cis-cleavage was initiated by addition of 5 µl of 250 mM MgCl2 and incubation 
at 37°C. Aliquots of 5 µl were removed at time points 0 and 20 minutes and cis-cleavage 
stopped by addition of 2 µl of RNA loading dye. The cis-cleavage reactions were run on a 41 
cm 10% denaturing polyacrylamide gel until the xylene cyanol dye front had run 
approximately 30 cm down the gel. The gel was subjected to autoradiography for 24 hours at
-70°C. 
 
2.4.3.3 Testing efficacy of Rz-shRNA expression cassette in cultured cells 
 
Transfections of Huh7 cells were carried out as described in Section 2.3.2, 6 µg of 
target/reporter plasmid (pCH-9/3091 for HBsAg quantitation and pCH-EGFP for green 
fluorescence detection) was co-transfected with 3 µg of pCI-Rz-shRNA vectors or empty pCI-
neo vector as a control. Quantification of markers of HBV replication was carried out as 
described in Section 2.3.3. 
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2.4.3.4 In vitro transcription of shRNA for transfection 
 
Transcription template was prepared by digesting pCI-Rz-shRNA vectors with BglII 
and SalI. Transcription reactions were carried out with the MEGAshortscript™ Transcription 
Kit (Ambion, TX, USA) according to the manufacturer’s instructions. Two to four 
micrograms of template was incubated with 10× Transcription buffer (Ambion, TX, USA), 
150 mM rGTP, 150 mM rATP, 150 mM rUTP, 150 mM rCTP and 2 µl Enzyme mix at 37°C 
for 24 hours.  
 
The transcription reaction was terminated by addition of 15 µl ammonium acetate, 
precipitated with ethanol and the RNA pellet resuspended in 50 µl of 100 mM Tris-HCl (pH 
8.0). Ten microlitre aliquots were heated to 95°C and allowed to cool to room temperature. 
The RNA sample was subjected to ribozyme cis-cleavage by addition of 10 µl of 100 mM 
MgCl2 and incubation at 37°C for 1 hour. Ribozyme cis-cleavage was terminated by addition 
of 5 µl RNA loading buffer. Cis-cleaved RNA was resolved on a 10% denaturing 
polyacrylamide gel until the xylene cyanol dye front was within 1.5-2.0 cm of the end of the 
gel. The gel was stained with SYBR gold (Invitrogen, CA, USA) and viewed on a UV 
transilluminator. Bands corresponding to the shRNA sequences were recovered from the gel 
by the crush and soak method (Appendix 6.1.6).  
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2.4.3.5 Transfection of cells with in vitro transcribed shRNA 
 
To test the efficacy of in vitro transcribed shRNA, Huh7 cells were co-transfected with 
4 µg pCH-9/3091 and 20 pmol of purified shRNA (70). Five hours before transfection Huh7 
growth medium was replaced with RPMI containing 10% FCS only. Four micrograms of the 
target vector and 20 pmol of the shRNA were diluted into 250 µl of Opti-MEM I. Three 
microlitres of Lipofectamine 2000 was diluted into 250 µl of Opti-MEM I and incubated at 
room temperature for 5 minutes. The diluted Lipofectamine was mixed with the diluted 
nucleic acid for 20 minutes at room temperature to allow nucleic acid-lipid complexes to form. 
Five hundred microlitres of the nucleic acid-lipid complex mixture was added per well to a 6-
well plate and mixed. The cells were incubated overnight at 37°C in a humidified incubator 
with 5% CO2. Fifteen hours post-transfection the medium was harvested and replaced with 
RPMI supplemented with 2.5% FCS and antibiotics. Medium was harvested again at 24 hours 
post-transfection. The medium was used to measure HBsAg secretion with the HBV Monolisa 
HBsAg ELISA (Bio-Rad, CA, USA), HBeAg secretion (Axsym immunoassay kit, Abbot 
Laboratories, IL, USA) and human interferon alpha and beta (Promega, WI, USA). 
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CHAPTER 3 
3 RESULTS 
3.1 U6 shRNA Expression Vectors Inhibit Markers of HBV Gene 
Expression 
3.1.1 U6 shRNA expression vectors inhibit EGFP expression 
 
Transient transfection of cultured cells with pCH-EGFP allowed for the use of 
fluorescence microscopy and flow cytometry in the detection of green fluorescent protein as a 
marker of HBV gene expression. The positive control included pCH-EGFP co-transfected 
with empty pGEM®-T Easy vector to confirm that any observed inhibition cannot be 
attributed to vector backbone. The cells shown in Figure 3.1 indicate representative 
fluorescence microscope fields of transfected cells. Cells transfected with pG-U6 shRNA2, 
pG-U6 shRNA8, pG-U6 shRNA10, pG-U6 shRNA11, pG-U6 shRNA12, pG-U6 shRNA14 and 
pG-U6 shRNA17 were able to significantly reduce EGFP expression. Transfection with pG-U6 
shRNA6 and pG-U6 shRNA7 exhibited a moderate reduction in EGFP expression and 
transfection with pG-U6 shRNA20 did not significantly alter EGFP expression.  
 
Flow cytometry allows for more accurate quantification of green fluorescent cells, 
therefore the transfected cells were analysed by flow cytometry. Transfections performed in 
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triplicate were averaged and the averages normalized to 1, where the number of green cells in 
the positive control equals 1 (Figure 3.2). The total numbers of green fluorescent cells indicate 
a statistically significant reduction at a confidence interval of 95% however the degree of 
reduction in EGFP was only moderate (30-50%).  
 
siRNA function by mediating the degradation of target mRNA. EGFP has a very long 
half-life; therefore any reduction in EGFP mRNA levels would not immediately be translated 
into a reduction in the protein levels. Using EGFP as a marker of HBV gene expression 
therefore underestimates the inhibitory effect of the U6 shRNA expression vectors. The 
cotransfection efficiency may also contribute to the moderate reduction in inhibition. The U6 
shRNA vectors may not have transfected with the same efficiency as the reporter plasmid. 
Some cells therefore may only contain the reporter plasmids and as such would be positive for 
EGFP. The degree of inhibition observed is therefore a function of cotransfection efficiency. 
 
3.1.2 U6 shRNA expression vectors reduce HBsAg secretion 
 
To assess the effects of U6 shRNA on HBsAg secretion growth medium was harvested 
from cells transiently transfected with the target plasmid, pCH-9/3091, and U6 shRNA 
expression vectors. Transfections were performed in triplicate, averaged and the values 
normalized to 1 (where 1 equals the total amount of secreted HBsAg from the positive 
control). HBsAg secretion reflect EGFP results; pG-U6 shRNA2, pG-U6 shRNA8, pG-U6 
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shRNA10, pG-U6 shRNA11, pG-U6 shRNA12, pG-U6 shRNA14 and pG-U6 shRNA17 
significantly inhibited HBV gene expression, pG-U6 shRNA6 and pG-U6 shRNA7 have 
moderate anti-HBV activity, whereas pG-U6 shRNA20 does not inhibit HBV gene expression 
(Figure 3.3). The high turnover of HBsAg gives a more accurate indication of the inhibitory 
effects of the U6 shRNA expression vectors. At a 95% confidence interval HBsAg was 
reduced by 80-90%.  
 
Results obtained from EGFP expression and HBsAg secretion were corroborated by 
Northern blotting. pG-U6 shRNA10 significantly knocked down levels of HBV RNA whereas 
pG-U6 shRNA7 only moderately knocked down HBV RNA and pG-U6 shRNA20 did not 
significantly reduce levels of HBV RNA (Carmona S, personal communication). 
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Figure 3.1: Representative fluorescence microscopy fields of Huh7 cells transfected with pCI-neo (A) pCH-
EGFP only (B), and pCH-EGFP co-transfected with pG-U6shRNA7 (C), pG-U6shRNA10 (D) and pG-
U6shRNA20 (E). 
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Figure 3.2: Representative flow cytometry histograms of Huh7 cells transfected with pCI-neo (A) pCH-EGFP 
only (B), and pCH-EGFP co-transfected with pG-U6shRNA7 (C), pG-U6shRNA10 (D) and pG-U6shRNA20 (E).  
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Figure 3.3: U6 promoter-derived shRNA mediated inhibition of EGFP expression as analysed by Flow Cytometry. Mean percentage of green 
fluorescent cells are indicated with the standard error of the mean. 
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Figure 3.4:  U6 promoter-derived shRNA mediated inhibition of HBsAg. Means of HBsAg secretion are indicated with the standard error of the 
means. 
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3.2 Selection of Rz-shRNA Sequences 
 
Approximately two in ten randomly chosen siRNA are effective at knocking down gene 
expression by 95% (71). Construction and validation of the Rz-shRNA expression cassettes is 
time consuming and labour intensive. Therefore a rapid technique for the validation of target 
sites is required. Algorithms are available for the rational design of effective synthetic siRNA 
sequences (71, 72); however these do not necessarily apply to shRNA sequences. The 
technique developed by Castanotto et al. (65) allows for the rapid generation and validation of 
shRNA expression cassettes. To test the Rz-shRNA expression cassette three U6 shRNA 
sequences were chosen; a highly effective shRNA (U6 shRNA10), a moderately effective 
shRNA (U6 shRNA7) and an ineffective shRNA (U6 shRNA20). U6 shRNA7, U6 shRNA10 
and U6 shRNA20 are equivalent to Rz shRNA1, Rz shRNA2 and Rz shRNA3, respectively. 
 
3.3 In vitro Transcription and Ribozyme Cis-cleavage Assays 
 
 
3.3.1 In vitro transcribed RNA undergo cis-cleavage 
 
 
To determine if the hammerhead ribozymes undergo cis-cleavage, RNA was transcribed 
from the three pCI-Rz shRNA expression vectors linearized with SalI and XhoI to produce the 
sense and antisense transcript, respectively (Figure 3.5). Hammerhead ribozymes require 
magnesium ions to undergo cis-cleavage. Ribozyme cis-cleavage is effected when the oxygen  
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Figure 3.5: Schematic representation of products generated from in vitro transcription using T7 and T3 RNA 
polymerases.  
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of the 2’-OH group acts as a nucleophile to form a bond with the phosphorus atom thereby 
breaking the bond between the phosphorus atom and the 5’-OH (73). Magnesium ions 
facilitate ribozyme cis-cleavage by stabilizing the intermediates between cleaved and 
uncleaved states. Since the transcription reaction is supplemented with MgCl2 ribozyme cis-
cleavage occurs as the RNA is transcribed. After an hour of in vitro transcription, the cleavage 
products were visible (i.e. 5’ ribozyme, shRNA and 3’ ribozyme) (Figure 3.6). Since the 
antisense transcripts have the complementary sequences for the hammerhead ribozymes no 
cleavage products were observed. The shRNA generated from cis-cleavage of Rz-shRNA2 is 
larger than those generated from cis-cleavage of Rz-shRNA1 and Rz-shRNA3. The resolution 
of the 10% polyacrylamide gel was high enough to resolve slight differences in the molecular 
weights of the three shRNA (shRNA1 = 21 844 Da, shRNA2 = 21 889 Da and shRNA3 
= 21 849 Da)  
 
3.3.2 Cis-cleavage of full-length transcripts yields cleavage products 
 
To confirm that the lower RNA bands were as a result of ribozyme cleavage, full-
length and intermediate cleavage products were excised from the gel and subjected to cis-
cleavage assays. The cis-cleavage assay reveals the full-length and intermediate RNA 
fragments decrease over time with a reciprocal increase in the cleavage products (Figure 3.7). 
Although the 5’ and 3’ hammerhead ribozyme undergo cis-cleavage the reaction is very 
inefficient since the full-length transcript was still present after a 20 minute incubation period
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Figure 3.6: Autoradiograph of in vitro transcription. Transcription from the T7 promoter generates sense strand 
RNA with catalytically active ribozymes whereas transcription with the T3 RNA polymerase generates 
catalytically inactive ribozyme sequences.  Active ribozymes undergo cis-cleavage to yield RNA fragments 
corresponding to the 5’ ribozyme, the shRNA and the 3’ ribozyme. Inactive ribozyme do not undergo cis-
cleavage and remain as full-length transcripts. 
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Figure 3.7: Ribozyme cis-cleavage assay. Full-length and intermediate sense transcripts were purified and 
subjected to a ribozyme cis-cleavage reaction. Over time the intensity of cleavage products (i.e. 5’ ribozyme, 
shRNA and 3’ ribozyme) increase with a concomitant decrease in the intensity of the full-length and intermediate 
transcripts.   
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in 50 mM MgCl2. In order to achieve efficient cis-cleavage at least five Watson-Crick base 
pairing is required in helix I. The inefficiency of ribozyme cis-cleavage may be attributed to 
the instability of helix I of the ribozyme, which only has three Watson-Crick base pairs (see 
Figure 2.3). This may prevent the ribozymes, especially the 3’ ribozyme from assuming the 
desired conformation thereby preventing cis-cleavage from occurring. 
 
3.3.3 Rz-shRNA expression vectors do not inhibit markers of HBV gene 
expression 
 
To test the ability of the Rz-shRNA expression to inhibit HBV gene expression pCI-Rz 
shRNA1, pCI-Rz shRNA2 and pCI-Rz shRNA3 were co-transfected with pCH-9/3091 and 
HBsAg secretion measured. Transfections done in triplicate were averaged and the averages 
normalized to 1, where 1 equals total HBsAg secreted by the positive control. None of the Rz-
shRNA expression vectors were capable of inhibiting HBV gene expression (Figure 3.8). This 
may be due to the fact that the vectors would endogenously produce a >1 kb fragment. Since 
the Rz-shRNA sequences are only approximately 200 nt in length the endogenously produced 
transcript also contains extraneous sequences. The extraneous sequences may not be 
conducive to proper folding of the ribozymes. Physiological conditions may also not favour 
ribozyme activity. Hammerhead ribozymes require divalent metal ions such as Mg2+ for 
efficient cleavage to occur. Intracellularly the free Mg2+ concentration is estimated to range 
between 0.1 and 0.5 mM (74). Ribozyme cis-cleavage assays were carried out at a Mg2+ 
concentration of 50 mM. After a 20 minute incubation full-length and intermediate transcripts 
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were still present demonstrating the inefficiency of the ribozymes especially the 3’ ribozyme. 
The inefficiency of the ribozymes coupled with the limited availability of Mg2+ in the 
physiological context contributed to the inability of the Rz-shRNA expression to suppress 
markers HBV replication. 
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Figure 3.8: CMV Rz-shRNA mediated inhibition of HBsAg secretion. Cells were co-transfected with pCI-Rz shRNA and pCH-3091. HBsAg secretion 
was normalized to 1, where 1 equals the total HBsAg secreted by the positive control. Means are indicated with SEM.  
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3.3.4 In vitro transcribed Rz-shRNA inhibits HBV gene expression 
 
To confirm that the inability of the Rz-shRNA expression cassettes to inhibit HBV 
gene expression was as a result of properties of the expression vector and not the shRNA 
sequence, Rz-shRNA1, Rz-shRNA2 and Rz-shRNA3 were prepared by in vitro transcription of 
the expression vectors (Figure 3.9). Huh7 cells were co-transfected with combinations of 
pCH-9/3091, Rz-shRNA1, Rz-shRNA2 and Rz-shRNA3. As expected Rz-shRNA1, which is 
equivalent to U6 shRNA7 only modestly knocked down HBsAg expression. Rz-shRNA2, 
which is equivalent to U6 shRNA10, was able to reduce HBsAg secretion to near baseline 
levels whereas Rz-shRNA3 (equivalent to U6 shRNA20) was unable to reduce HBsAg 
secretion significantly (Figure 3.10).  
 
HBsAg can be expressed directly from pCH-9/3091 and therefore although HBsAg 
secretion from cells transfected with pCH-9/3091 correlates well with HBV replication strictly 
speaking it is not a direct marker of HBV replication. pCH-9/3091 is designed such that 
HBeAg is not expressed directly from the plasmid. Cells transfected with pCH-9/3091 only 
express HBeAg if cccDNA is formed (i.e. if replication occurs) (68). HBeAg secretion is 
therefore a direct marker of HBV replication. The effect of in vitro transcribed Rz-shRNA on 
HBeAg secretion was therefore also measured (Figure 3.11). HBeAg secretion did not 
correlate well with HBsAg secretion. The differences in suppression may be an indication that 
the 3.5 kb message encoding HBeAg has a different susceptibility profile to
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Figure 3.9: Rz-shRNA purification. RNA produced from run-off transcription of linearized pCI-Rz shRNA were subjected to polyacrylamide gel 
electrophoresis (A), the bands corresponding to the Rz-shRNA identified and purified by the crush and soak method. The purified Rz-shRNA were 
subjected to polyacrylamide gel electrophoresis to check RNA quality (B). 
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Figure 3.10: Rz-shRNA mediated inhibition of HBsAg secretion. Cells were co-transfected with in vitro transcribed Rz-shRNA and pCH-3091. 
HBsAg secretion was normalized to 1, where 1 equals the total HBsAg secreted by the positive control. The means are indicated with the SEM. 
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Figure 3.11: Rz-shRNA mediated inhibition of HBeAg secretion.  In vitro transcribed shRNA and pCH-9/3091 were used to co-transfect Huh7 cells, 
the medium harvested at 24 hours and HBeAg secretion measured. HBeAg secretion was normalized to 1, where 1 equals the total HBeAg secreted by 
the positive control. The means are indicated with the SEM.  
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shRNA mediated inhibition than the 2.1 kb message encoding HBsAg (75). 
 
3.4 Interferon-alpha and interferon-beta secretion 
 
The use of RNAi to knockdown gene expression in mammalian cells can only be 
achieved through the use of siRNA as dsRNA greater than 30 bp induces the interferon 
response. Chemically synthesized siRNA, shRNA expression vectors as well as in vitro 
transcribed siRNA have been demonstrated to induce the interferon response (55, 76, 77). To 
determine whether the observed effects (i.e. knockdown of HBV gene expression) could be 
attributed to a specific RNAi-mediated pathway or to a non-specific interferon response 
interferon-α and interferon-β secretion from cells co-transfected with pCH-9/3091 and in vitro 
transcribed shRNA measured (Figures 3.11 and 3.12). Interferon secretion was either not 
significantly different from baseline (interferon-α) or significantly lower (interferon-β) than 
baseline. The significant decrease in interferon-β cannot be explained however, since 
interferon secretion (α and β) was not raised it may be concluded that the observed knockdown 
of HBV gene expression is not due to a non-specific interferon response. 
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Figure 3.12: Interferon-alpha secretion. Interferon-α secretion from Huh7 cells co-transfected with pCH-9/3091 and in vitro transcribed shRNA was 
measured 24 hours post-transfection. 
Chapter 3  - 66 - 
 
Figure 3.13: Interferon-beta secretion. Growth medium from Huh7 cells co-transfected with in vitro transcribed shRNA and pCH-9/3091 were 
analysed for interferon-β secretion at 24 hours post-transfection. 
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CHAPTER 4 
4 DISCUSSION 
 
Results presented in this study as well as other studies demonstrate that siRNA (10-13) 
and vector-expressed shRNA (14, 15) are capable of efficiently mediating RNAi against HBV. 
The use of RNAi as a treatment modality for the management of chronic HBV infection 
therefore holds much promise.  
 
4.1 Efficacy of shRNA 
 
The ability of any given siRNA to mediate efficient gene knockdown has been shown to 
be dependent on several sequence-specific criteria (71). Reynolds and colleagues identified 
eight criteria that confer functionality to a siRNA. These include a GC content of 30%-52%, 3 
or more A/U pairs at positions 15-19, lack of internal repeats with Tm < 20°C, an A base at 
positions 3 and 19, a U base at position 10, an A or U base at position 19 and an A, U or C at 
position 13 (with the positions of the bases given with reference to the sense strand). The first 
four criteria are important during the initial steps of RNAi (i.e. siRNA uptake by RISC, strand 
selection and duplex unwinding). The remaining criteria identify base preferences, which may 
be important in the final stages of RNAi (i.e. target recognition and mRNA cleavage). The 
sequences of the U6 shRNA and Rz-shRNA were analysed and scored based on the eight 
criteria (see Table 4.1 and Figure 4.1).  
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Table 4.1:  Scoring table for predicting shRNA efficacy
 
 30-50%  
GC 
Content 
3 AU bases 
at positions 
15-19 
Absence of 
Internal 
Repeats 
A at 
position  
19 
A at 
position  
3 
U at 
position 
10 
A or U at 
position 
19 
A, U or C at 
position 
13 
 
Total Score 
U6 shRNA2 1 (52%)  3 1 1 1 0 1 1 9 
U6 shRNA6 0 (76%) 0 1 1 0 0 1 1 4 
U6 shRNA7
Rz-shRNA1
0 (72%) 1 0 0 1 0 1 1 4 
U6 shRNA8 0 (62%) 3 1 0 0 1 0 1 6 
U6 shRNA10
Rz-shRNA2
0 (57%) 3 1 0 0 0 1 1 6 
U6 shRNA11 0 (57%) 2 1 1 0 0 1 1 6 
U6 shRNA12 1 (43%) 5 0 1 1 0 1 1 10 
U6 shRNA14 1 (48%) 3 0 1 0 0 1 1 7 
U6 shRNA17 1 (43%) 4 0 0 0 0 1 1 7 
U6 shRNA20
Rz-shRNA3
0 (57%) 2 1 0 0 0 1 1 5 
Tm of internal loops determined with Gene Runner (78) 
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Figure 4.1: Predicted secondary structures of (A) U6 shRNA and (B) Rz-shRNA. Scores were generated against the sequences indicated in bold. 
Secondary structures predicted from design.  
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The eight criteria identified by Reynolds and colleagues were determined through the 
analysis of synthetically produced siRNA 19 bp in length. These criteria may therefore not be 
accurate at predicting effective shRNA sequences. This point is illustrated by the sequences of 
U6 shRNA10 and its equivalent Rz-shRNA2, which were effective at inhibiting HBV 
replication but scored low (Table 4.1). Similarly, U6 shRNA8, U6 shRNA11, U6 shRNA14 and 
U6 shRNA17 although effective at knocking down HBV replication received low scores. Other 
criteria, not necessarily excluding the eight listed, may be more important in determining 
efficacy of shRNA. 
 
Primer extension analysis of cells transfected with pG-U6 shRNA10 and pG-U6 
shRNA20 revealed that U6 shRNA10 was processed efficiently into a siRNA whereas U6 
shRNA20 remained unprocessed (Carmona S, personal communication). Processing of shRNA 
by Dicer is therefore an important factor in determining the efficacy of a shRNA. The 
sequence requirements facilitating processing by Dicer are as yet unknown. 
 
4.2 Endogenous versus Exogenous shRNA production 
 
This project adopted two approaches for the generation of shRNA targeted to the HBx 
ORF of HBV. The first expression cassette involved the endogenous production of shRNA 
driven by the U6 promoter whereas the second expression cassette allowed for the in vitro 
production of shRNA from a phage promoter (i.e. the T7 promoter). Each expression cassette 
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has its own advantages as well as shortcomings. Neither expression cassette influenced the 
anti-HBV modulatory power of the expressed shRNA sequence. A shRNA sequence 
expressed endogenously from the U6 promoter was equally capable of inhibiting HBV 
replication as the same shRNA sequence produced from in vitro transcription. Both U6 
shRNA7 and Rz-shRNA1 exhibited moderate anti-HBV activity, both U6 shRNA10 and Rz-
shRNA2 were capable of inhibiting HBV replication to near baseline levels and U6 shRNA20 
and Rz-shRNA3 were unable to inhibit replication of the virus. The observed degree of HBV 
gene knockdown was therefore determined wholly by the shRNA sequence without any 
contribution from the cassette it was expressed from.  
 
The merit of using either approach is therefore defined by the innate advantages as well 
as the disadvantages of endogenous or exogenous shRNA production. RNAi-mediated gene 
silencing can only be maintained as long the DNA or RNA inducing RNAi remains stable. 
DNA has a longer half-life than RNA and as such the use of expression cassettes to 
endogenously generate shRNA maintain gene knockdown for longer periods than shRNA 
produced exogenously. DNA expression cassettes also allow for versatility of delivery in that 
both viral and non-viral vectors may be used to deliver the expression cassette whereas only 
non-viral vectors may be used for the delivery of exogenously produced shRNA. siRNA-
mediated post-transcriptional gene silencing occurs in the cytoplasm therefore the shRNA, 
whether produced endogenously or exogenously, needs to reach the cytoplasm. The use of 
exogenously produced shRNA therefore only requires that the plasma membrane be crossed 
whereas expression cassettes need to cross the plasma membrane as well as the nuclear 
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membrane to exert an effect. The amount of shRNA generated from the endogenous 
transcription of the expression cassettes cannot be controlled therefore the dose cannot be 
controlled. The use of exogenously produced shRNA however does allow for the dosage to be 
controlled. Although the Rz-shRNA expression cassette could only knockdown HBV 
replication through the exogenous production of shRNA it has the potential to be used for both 
the endogenous and exogenous production of shRNA. 
 
4.3 Off-target Effects 
 
To identify sites within the human genome, which may be targeted by the panel of 
shRNA, the HBx target sites were subjected to a BLAST search. None of the HBx target sites 
were completely homologous to regions within the human genome. The search results 
returned 98 hits for HBx1168-1192 (U6 shRNA2 target site) of which 5 were significant.  The first 
hit shows a 22/24 nt match, with the two mismatches lying close to the centre of the sequence, 
and is therefore unlikely to be silenced as mismatches close to the centre of the siRNA/mRNA 
duplex abolish silencing (79). The remaining 4 hits showed 18/19 nt matches. HBx1640-1664 (U6 
shRNA12 target site) and HBx1575-1599 (U6 shRNA20 target site) were not significantly 
homologous to any region within the human genome. HBx1618-1542 (U6 shRNA8 target site) is 
95% homologous to a region of a human cDNA clone (19/20 nt match) however the mismatch 
lies close to the centre of the target site U6 shRNA8 is therefore unlikely to silence this 
mRNA. HBx1678-1702 (U6 shRNA14 target site) is significantly homologous to a human 
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expressed sequence tag (23/24 nt match) and may exhibit off-target effects. The remaining 
shRNA from the panel exhibit 18/19 nt matches with human cDNA clones. 
 
Post-transcriptional gene silencing of a target mRNA by siRNA and miRNA is achieved 
in one of two ways, mRNA degradation or translational repression. The degree of 
complementarity between the siRNA or miRNA and the target mRNA determines whether 
silencing is through mRNA degradation or translational repression (45-48). If the siRNA or 
miRNA is completely complementary to the target silencing will occur through mRNA 
degradation. If incomplete complementarity exists between the target and the siRNA or 
miRNA silencing will be mediated through translational repression. A siRNA designed to be 
completely complementary to its target could theoretically exhibit incomplete 
complementarity to an undesired target. siRNA could therefore be predicted to mediate off-
target gene silencing through translational repression.  
 
Off-target gene regulation has been reported (80), however the results are questionable. 
Expression profiles demonstrated silencing of genes sharing as little as 8 complementary 
nucleotides with the siRNA. Silencing was demonstrated to occur by rapid kinetics indicating 
degradation events and not, as would be predicted, translational repression. Similar gene 
expression profiling done by two separate groups contradicted the first study (81, 82). A recent 
study argues against off-target effects (83). mRNA contain numerous sites targeted by 
miRNA. Only when single copies of different miRNA species or multiple copies of a single 
miRNA function synergistically is translational repression achieved. Therefore a siRNA 
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incompletely complementary to a single site on an mRNA sequence is unlikely to repress its 
translation.  
    
4.4 The Interferon Response 
 
Interferons function as antiviral cytokines in mammalian and avian systems as the first 
line of defence against viral infection. This is usually mediated by dsRNA as most viruses 
produce dsRNA at some point in their replicative life cycle. dsRNA binds and activates 
enzymes, which induce the interferon response. Binding of dsRNA to the dsRNA-activated 
Protein Kinase, PKR, activates the kinase by inducing autophosphorylation of this dimeric 
protein (25). Activated PKR phosphorylates and activates the α subunit of the eukaryotic 
translation initiation factor 2 (eIF-2α). Activated eIF-2α rapidly leads to the global shutdown 
of protein synthesis. 2’-5’ Oligoadenylate synthetases (2’-5’ OASs) are also activated upon 
binding to dsRNA and catalyze the polymerization of ATP into 2’-5’ linked oligoadenylates 
(26). The oligoadenylates in turn bind and activate RNase L, which leads to the non-specific 
degradation of mRNA.  
  
Initial RNAi experiments in mammalian cells were hampered by the induction of the 
interferon response as large dsRNA molecules were being used. The discovery that Dicer 
processing of the large trigger dsRNA could be bypassed (21), demonstrated that RNAi could 
be induced without inducing the interferon response. Since only dsRNA greater than 30 bp in 
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size induce the interferon response the use of siRNA, which are 21-22 nt in length, allowed for 
the use of RNAi in mammalian cells (27, 28). 
 
Recently it was demonstrated that siRNA produced from in vitro transcription using 
phage polymerases (T7, T3 and SP6 polymerases) induce the interferon response (55). In vitro 
transcription from phage polymerases generates RNA with 5’ triphosphates. RNA species 
containing 5’ triphosphates are recognized by mammalian cells as viral in nature and therefore 
induce an interferon response. The Rz-shRNA cassettes described here allows for the in vitro 
production of shRNA from the T7 phage polymerase. However unlike previously described 
methods for the in vitro production of siRNA this method requires a ribozyme cis-cleavage 
step. As a result the 5’ phosphate (which occurs on the 5’ ribozyme) does not occur on the 
shRNA. The Rz-shRNA cassette therefore improves on the design of in vitro transcribed 
siRNA or shRNA as it bypasses induction of the interferon response through removal of the 5’ 
triphosphate.    
  
4.5 Delivery    
 
 
In order to mediate inhibition of HBV the siRNA, shRNA or systems expressing the 
siRNA/shRNA sequences need to be effectively delivered to the liver. Delivery is the major 
hurdle facing any form of gene therapy.  
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Recombinant viral vectors have been generated carrying shRNA expression vectors (84, 
85) and allow for the endogenous of shRNA capable of mediating RNAi. The use of 
recombinant viral vectors cannot be used in conjunction with exogenously produced siRNA or 
shRNA. The risks associated with recombinant viruses severely limit their application in gene 
therapy. Retroviruses, for example, are able to integrate into the genome of the host cell. 
Should the integration event disrupt normal gene expression, especially of genes involved in 
cellular proliferation, tumourogenesis could occur. As a fail-safe mechanism recombinant 
viruses are usually devoid in a gene or genes essential for viral replication making the 
recombinant virus replication-defective. Packaging cell lines complement replication-defective 
viruses since these cells express the gene or genes that the virus is deficient in. The possibility 
therefore still exists that a recombination event could occur within the packaging cell line, 
which would generate a replication-competent virus. 
 
A safer option is the use of cationic lipids to deliver nucleic acids to cells. This method 
allows for the use of exogenously produced siRNA or shRNA as well as expression systems 
capable of endogenously generating siRNA or shRNA sequences.  The development of lipid-
based delivery systems exhibiting cell tropism remains an important objective. A novel 
approach to the development of cell tropic lipids was demonstrated recently. Numerous 
enveloped viruses exhibit cell tropism, due to specific interactions between viral receptors 
embedded within the viral envelope and host cell receptors. Yamada and colleagues generated 
nanoparticles (called L particles) by transfecting yeast cells with plasmids expressing the large 
surface antigen of HBV (86). The L particles were virion free. These particles were shown to 
Chapter 4  - 77 - 
exhibit hepatotropism and were capable of efficiently delivering nucleic acids in addition to 
other molecules to hepatocytes. A major drawback to this technology was that the L particles 
were unable to transduce human HCC cells (PLC/PRF/5 cells). HBsAg particles containing L 
protein released by the cell line out competing L particles for host cell receptor sites is thought 
to be the reason for the inability of these nanoparticles to efficiently deliver to HCC cells.  
 
The use of steroid and lipid conjugates linked to the 3’ ends of synthetic siRNA have 
been demonstrated to enhance uptake of the siRNA by liver cells (87). Chemically modified 
siRNA molecules with conjugated cholesterol moieties have also been used as delivery 
systems in vivo after systemic administration (88). Since the liver is an important site of 
cholesterol biogenesis it has numerous receptors dedicated to the uptake of cholesterols. The 
receptors are presumably responsible for the increased uptake of cholesterol bound nucleic 
acids (89). 
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CHAPTER 5 
5 CONCLUSION 
 
In this study the construction and evaluation of expression cassettes capable of the 
endogenous and exogenous generation of shRNA is described. This study is the first to 
describe a self-cleaving cassette capable of endogenously and exogenously generating shRNA 
of precisely defined length.  
 
The work presented here details a novel method for the in vitro production of shRNA by 
phage polymerases. The use of phage polymerases for the in vitro generation of siRNA or 
shRNA is complicated by the incorporation of 5’ triphosphates in the RNA transcript. The 
presence of 5’ triphosphates on RNA transcripts has been shown to induce the sequence non-
specific interferon response. In vitro production of shRNA from the Rz-shRNA expression 
cassette requires ribozyme cis-cleavage events, which generates a shRNA sequence devoid of 
any 5’ triphosphates. Although the Rz-shRNA expression cassettes were unable to mediate 
efficient knockdown of HBV replication, shRNA produced from in vitro transcription of the 
Rz-shRNA expression cassette were equally capable of inhibiting HBV replication as shRNA 
generated from conventional U6 promoter-driven expression. 
 
siRNA expression systems favour the use of RNA polymerase III promoter as these are 
normally involved in the transcription of short RNA species and as such are ideal for the 
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generation of siRNA. The Rz-shRNA expression cassette employs ribozyme cis-cleavage to 
generate shRNA of exact size and is therefore not limited to the use of RNA polymerase III 
promoters. Since RNA polymerase II promoters exhibit tissue-specificity the Rz-shRNA 
expression cassette lends itself to tissue-specific expression of shRNA.  
 
Knockdown of gene expression could not be achieved through the use the Rz-shRNA 
expression cassette. This may be due to the inability of the hammerhead ribozymes to undergo 
cis-cleavage in a physiological context. Free Mg2+ concentration within cells is well below the 
level required for hammerhead ribozyme to undergo catalysis. The Rz-shRNA expression 
cassette can be improved upon by the incorporation of ribozyme sequences capable of 
efficient cis-cleavage at physiological Mg2+ concentrations. 
 
The Rz-shRNA expression cassette expands and improves on the repertoire of siRNA 
expression systems. The results presented in this study demonstrate the potential effectiveness 
in using the Rz-shRNA expression cassette for the knockdown of gene expression. 
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6 APPENDIX 
6.1 Laboratory Techniques 
6.1.1 Preparation and transformation of chemically competent E. coli 
 
Reagents  
Luria Bertani medium 
Ten grams of Bacto-tryptone (Oxoid, England), 5 g Yeast extract (Oxoid, England) 
and 5 g NaCl were dissolved per litre of deionized water. The medium was autoclaved 
for 30 minutes at 121°C and 1 kg/cm2.  
 Transformation buffer 
Transformation buffer was prepared as follows: 100 mM CaCl2, 10 mM PIPES-HCl 
and 15% Glycerol. The pH was adjusted to 7.0 with NaOH and the solution autoclaved 
for 30 minutes at 121°C and 1 kg/cm2. Transformation buffer is stored at -20°C. 
 
Protocol 
 Preparing chemically competent E. coli 
Fifty millilitres of Luria Bertani medium was inoculated with a single colony of the 
desired strain of E. coli (DH5α or GM161). The culture broth was incubated at 37°C 
with shaking until the Absorbance read at 600 nm was 0.4. The cells were centrifuged 
at 2500 rpm for 5 minutes and the pellet resuspended in 10 ml Transformation buffer 
followed by a 20 minute incubation on ice. After the 20 minute incubation period the 
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cells were centrifuged at 2500 rpm for 5 minutes and the pellet resuspended in 1 ml of 
Transformation buffer. Aliquots of 100 µl were transferred to sterile microcentrifuge 
tubes and stored at -70°C. 
Transforming chemically competent E. coli 
One hundred microlitres of competent E. coli was added to 5-10 µl of ligation mix and 
incubated on ice for 30 minutes. After the 30 minute incubation period the cells were 
heat shocked at 42°C for 90 seconds and placed on ice for an additional 2-5 minutes. 
Transformed bacteria were then plated on Luria Bertani agar plates containing 
selective antibiotics. 
 
6.1.2 α-Complementation 
Reagents 
 1000× Ampicillin 
One hundred milligrams of ampicillin (Roche, Germany) was dissolved in 1 ml of 50% 
ethanol.  
Ampicillin positive Luria Bertani agar plates 
Ten grams Bacteriological agar (Oxoid, England), 10 g Bacto-tryptone (Oxoid, 
England), 5 g Yeast extract (Oxoid, England) and 5 g NaCl were dissolved per litre of 
deionized water. The solution was autoclaved for 30 minutes at 121°C and 1 kg/cm2. 
1000× ampicillin was added to a final concentration 100 µg/ml. Luria Bertani agar was 
poured into Petri dishes and allowed to solidify at room temperature. 
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5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) stock solution 
Twenty milligrams of X-gal (Sigma, MO, USA) was dissolved in 1 ml dimethyl 
formamide. The solution is light-sensitive and is therefore covered with aluminium foil 
and stored at -20°C. 
 Isopropyl-β -D-thiogalactopyranosid (IPTG) stock solution 
Two hundred milligram of IPTG (Roche, Germany) was dissolved in 1 ml sterile 
water. 
 
Protocol 
 Preparing IPTG, X-gal positive Luria Bertani agar plates 
Forty microlitres of X-gal stock solution and 8 µl of IPTG stock solution were added to 
an ampicillin positive Luria Bertani agar plate and spread evenly on the surface. The 
plates were dried in an incubator at 37°C for 30 minutes and stored at 4°C. 
Transformed E. coli are plated on ampicillin positive, X-gal, IPTG positive agar plates 
and incubated at 37°C overnight for α-complementation. IPTG induces expression of 
β-galactosidase, which cleaves the chromogenic substrate X-gal yielding a blue 
product. Successful cloning (plasmids positive for an insert) disrupts the β-
galactosidase gene and therefore the protein is not functional resulting in white 
colonies. Unsuccessful insertion of fragments leaves the β-galactosidase intact 
resulting in blue colonies. 
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6.1.3 EndoFree® Plasmid Maxi Kit plasmid preparation 
Reagents 
 Luria Bertani medium 
 See Appendix 6.1.1 
EndoFree® Plasmid Maxi Kit (Qiagen, CA, USA) 
 
Protocol 
Three hundred millilitres of Luria Bertani medium was inoculated with a single colony 
containing the plasmid of interest and incubated at 37°C with shaking (100 rpm) for 18 
hours. The cells were pelleted by centrifugation at 4000 rpm for 20 minutes at 4°C and 
the pellet resuspended in 10 ml Resuspension buffer (Buffer P1; 50 mM Tris-HCl, pH 
8.0; 10 mM EDTA) containing RNAse A at a concentration of 100 µg/ml. Ten 
millilitres of Lysis buffer (Buffer P2; 200 mM NaOH; 1% SDS) was added to the cell 
suspension, the solution mixed thoroughly and incubated at room temperature for no 
more than 5 minutes. Ten millilitres of the Neutralization buffer (Buffer P3; 3 M KAc, 
pH 5.5) was added to the lysate, mixed, applied to the Qiafilter Cartridge and 
incubated at room temperature for 10 minutes. After the 10 minute incubation, the 
lysate was filtered into a sterile 50 ml tube. Two and a half millilitres of Endotoxin 
removal buffer (Buffer ER) was added to the filtrate, mixed and incubated on ice for 
30 minutes. During the incubation on ice a QIAGEN-tip 500 was equilibrated by 
applying the Equilibration buffer (Buffer QBT; 750 mM NaCl; 50 mM MOPS, pH 7.0; 
15% Isopropanol; 0.15% Triton® X-100) to the column and allowing the buffer to 
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drain by gravity flow. After the incubation in Endotoxin removal buffer the solution 
was applied to the QIAGEN-tip and allowed to drain by gravity flow. The column was 
washed with 30 ml Wash buffer (Buffer QC; 1 M NaCl; 50 mM MOPS, pH 7.0; 15% 
Isopropanol), twice. The plasmid was eluted from the column with 15 ml Elution 
buffer (Buffer QN; 1.6 M NaCl; 50 mM MOPS, pH 7.0; 15% Isopropanol). A 0.7× 
volume of isopropanol was used to precipitate the plasmid. The DNA was centrifuged 
at 8000 rpm for 1 hour at 4°C. The DNA pellet was washed with endotoxin-free 70% 
ethanol and re-centrifuged at 8000 rpm at 4°C for an hour. The pellet was air-dried and 
resuspended in an appropriate volume of endotoxin-free TE buffer (10 mM Tris-HCl, 
pH 8.0; 1 mM EDTA). 
 
6.1.4 Tissue culture 
Reagents 
 RPMI medium (RPMI) 
One litre of RPMI was made as follows: 10.4 g of RPMI-1640 (Gibco BRL, United 
Kingdom), 5.0 × 10-3M HEPES, 3.0 × 10-8M Na2SeO3, 3.0 × 10-9 (NH4)6Mo7O2·4H2O, 
1.0 × 10-7 M FeSO4·7H2O, 3.0 × 10-10M MnCl2·4H2O, 1.0 × 10-8 M NH4VO3, 3.0× 10-9 
M linoleic acid, 3.0 × 10-9 M oleic acid, 3.0 × 10-5 M ethanolamine and 2.4 × 10-2 M 
NaHCO3. The medium was sterilized by filtration. 
FCS (delta bioproducts, South Africa) 
1000× Pen/Strep 
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0.61 g of Penicillin and 1 g of Streptomycin was dissolved in 10 ml of deionized water 
and the solution filter sterilized. 
Saline + 0.01% EDTA 
0.5× Trypsin 
Five hundred microlitres of a 10× stock solution was made up to 10 ml and filter 
sterilized. 
  
 
Protocol 
Huh7 cells were maintained in a humidified incubator at 37°C and 5% CO2 in RPMI 
growth medium supplemented with 2.5% FCS and antibiotics. When cells reached a 
density covering 90% of the culture dish surface the cells were passaged. The cells 
were washed once with saline followed by a 5 minute incubation at 37°C in saline 
containing 0.01% EDTA. Following the 5 minute incubation the saline-EDTA solution 
was removed, 500 µl of 0.5× trypsin added and the cells incubated for an additional 5 
minutes. The cells were then dislodged from the culture dish by gentle aspiration. An 
equal volume of conditioned medium was added to inactivate the trypsin. Cells were 
added to a sterile 10 cm2 tissue culture dish at the desired density (30-40%). Ten 
millilitres of RPMI was added and the cells incubated at 37°C and 5% CO2 in a 
humidified incubator. Growth medium was replenished at 48 hour intervals until cells 
needed to be passaged.  
For transfections, Huh7 cells were grown to a density of 90-100%. The growth 
medium was removed and the cells washed with saline. Following the wash the cells 
were incubated in saline containing 0.01% EDTA for 5 minutes. The saline-EDTA was 
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removed and the cells trypsinized at 37°C for 5 minutes. Two hundred- to two hundred 
and fifty-thousand cells were seeded per well in a 6-well plate and the cells grown 
overnight at 37°C and 5% CO2 in RPMI supplemented with 2.5% FCS and antibiotics. 
Five hours before transfection the growth medium was removed and replaced with 
RPMI supplemented with 10% FCS and no antibiotics.  
 
6.1.5 Manual sequencing 
 
Reagents 
 SequiTherm EXCEL™ II DNA Sequencing Kit (Epicentre®, WI, USA). 
 T7/T3 unlabeled primer 
 T7 primer sequence: 5’- TTA ATA CGA CTC ACT ATA -3’ 
 T3 primer sequence: 5’- CAT TAA CCC TCA CTA AAG -3’ 
 α-32P dATP (3000 Ci/mmol; Amersham, United Kingdom) 
 10× Tris-Borate EDTA (TBE) buffer 
Fifty four grams of Tris, 27.5 g of Boric acid and 20 ml of 0.5M EDTA (pH 8.0) were 
dissolved in 500 ml of deionized water and sterilized by autoclaving at 121°C and
1 kg/cm2. 
8% denaturing polyacrylamide gel 
 Eight grams of Acrylamide and bis-acrylamide (at a ratio of 19:1) per 100 ml  
 7 M Urea 
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 Ten millilitres of 10× TBE 
 
Protocol 
In a 17 µl reaction volume, a master mix containing 1.5 pmol of unlabeled primer (T7 
or T3), 0.5-1.0 µg of plasmid DNA (pCI-Rz-shRNA), 7.2 ml 3.5× SequiTherm 
EXCEL™  II Sequencing Buffer, 10 µCi α-32P dATP, and 5 U of SequiTherm 
EXCEL™ II DNA Polymerase. Two microlitres of ddGTP, ddATP, ddTTP and 
ddCTP were added separately to four sterile 0.5 ml microcentrifuge tubes. Four 
microlitres of the master mix was added to each of the tubes containing ddNTPs. The 
mixture was denatured at 95°C for 5 minutes. The cycling parameters were as follows: 
30 cycles of 30 seconds at 95°C and 1 minute at 70°C. Upon completion of the cycling, 
3 µl of Stop/Loading Dye was added to the sequencing reactions. Before loading the 
sequencing reactions the samples were heated at 95°C for 5 minutes. Three microlitres 
of the sequencing reactions were loaded per well in the order G-A-T-C and resolved on 
an 8% denaturing polyacrylamide gel at 60 W. The samples were run until the 
bromophenol blue dye front reached the end of the gel. The gel was removed from the 
plates and subjected to autoradiography at -70°C for 30 minutes to an hour. 
 
 
6.1.6 RNA recovery from polyacrylamide gel 
Reagents 
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 Diethyl pyrocarbonate (DEPC)-treated water 
One millilitre of DEPC was added to a litre of deionized water. DEPC treatment was 
allowed to proceed overnight. DEPC was inactivated by autoclaving at 121°C and 
1 kg/cm2 for 30 minutes. 
Elution buffer 
The Elution buffer was prepared as follows: 20 mM Tris (pH 7.5), 0.5 M Sodium 
acetate (pH 5.2), 10 mM EDTA (pH 8.0) and 1% SDS. All solutions were prepared 
with DEPC-treated water. 
 
Protocol 
A sharp, clean blade was used to excise the gel slice containing RNA of interest. The gel 
slice was transferred to a sterile microcentrifuge tube and crushed with a filtered pipette 
tip. Two hundred microlitres of the Elution buffer was added per gel slice and incubated 
at 37°C with agitation overnight. After the overnight incubation the solution was 
centrifuged at 10 000 rpm for 10 minutes. The supernatant was carefully removed to a 
clean microcentrifuge tube and the RNA ethanol precipitated. A 0.1× volume of 3M 
Sodium acetate and an equal volume of 100% ethanol was added to the supernatant and 
incubated at -20°C for an hour. After the hour incubation the RNA was precipitated at 
13 000 rpm for 30 minutes at 4°C.  The RNA pellet was washed in 70% ethanol and re-
centrifuged at 13 000 rpm for 10 minutes at 4°C. RNA to be used for ribozyme cis-
cleavage assays was resuspended in 62.4 mM Tris-HCl. The RNA to be used in 
transfections was resuspended in Endotoxin free TE buffer (Qiagen, CA, USA).
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